GABITRIL (tiagabine hydrochloride; CEP-6671)
C6671A/301/AX/US
Phase 3 small_molecule completed
Quick answer
GABITRIL (tiagabine hydrochloride; CEP-6671) for General Anxiety Disorder is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- General Anxiety Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed